Anthem Biosciences share price: Stock makes robust debut at 27% premium; here's how much investors made per lot

On the BSE, it started trading at ₹723.10, up 26.86%.

Anthem Biosciences share price: Here's how much investors made per lot

The initial public offer was subscribed to 63.86 times, as investors placed bids for 2,81,45,24,128 equity shares as against 4,40,70,682 shares offered, according to the consolidated data on the NSE.

Qualified institutional buyers (QIBs) led the bidding as they subscribed to the part reserved for them 182.65 times, followed by non-institutional investors (NIIs) who booked their part 42.35 times, and retail individual investors at 5.64 times subscription.

The Bengaluru-based company was seeking to raise ₹3,395.79 crore by solely an offer for sale component of 5.96 crore shares. There was no fresh issuance of shares.

Under the OFS, K Ravindra Chandrappa, Ganesh Sambasivam, Portsmouth Technologies LLC, Viridity Tone LLP, Rupesh N Kineka, Malay J Barua, Prakash Kariabettan, Satish Sharma and K Ramakrishna offloaded their stake.

The price band was fixed at ₹540-₹570 per share.

Nomura Financial Advisory and Securities (India), Citigroup Global Markets India, JP Morgan India, and JM Financial were the IPO's book-running lead managers.

Before the IPO, the company had raised ₹1,016 crore from anchor investors, including Government Pension Fund Global, Abu Dhabi Investment Authority, Eastspring Investments, PineBridge Global Funds, Amundi Funds, Societe Generale, HDFC MF (MF), Axis MF, UTI MF, Quant MF, ICICI Prudential MF, and Motilal Oswal MF.

Anthem is a contract research, development and manufacturing organisation (CRDMO) with operations spanning across drug discovery, development and manufacturing.

It also produces and sells complex, specialised fermentation-based Active Pharmaceutical Ingredients (APIs) such as probiotics, enzymes, nutritional actives, peptides, vitamin analogues and biosimilars.